AstraNova's phased drug discovery model is designed so that insights from each stage directly inform the next — creating a scientifically coherent path from concept to clinic.
We will help translate the next go/no-go decision into a focused workplan across pharmacology, screening, ADME, and translational biology.
The foundation of any successful drug discovery program is a rigorously validated target with clear evidence of disease relevance, modifiability, and druggability. AstraNova partners with clients in the earliest stages of target biology to build the scientific case that justifies downstream investment.
With a validated target and qualified primary assay, AstraNova designs and executes screening campaigns to identify active chemical matter. Our HTS facility supports biochemical, cell-based, and fragment-based screening across multiple discovery paradigms.
Transforming a screening hit into a viable lead scaffold requires rapid iterative assessment of potency, selectivity, and preliminary ADME properties. AstraNova's hit-to-lead platform is designed to provide the multiparametric data feedback that medicinal chemistry teams need at decision-relevant speed.
The lead optimization phase demands the most intensive multiparameter scientific support. AstraNova's optimization platform integrates pharmacology, ADME, selectivity, and mechanistic pharmacology data into a continuously updated multi-parameter optimization (MPO) scoring framework.
The IND-enabling phase requires a comprehensive, regulatory-ready preclinical data package demonstrating safety, mechanism, and rationale for the chosen clinical dose and indication. AstraNova coordinates the scientific content assembly with regulatory strategy awareness.
Bring us the program question, constraints, and next decision point. We will map the right assays, controls, timeline, and reporting package before the first plate is run.
